Bifeprunox: A novel antipsychotic agent with partial agonist properties at dopamine D2 and serotonin 5-HT1A receptors

Future Neurology

Volumn 2, Issue 2, 2007, Pages 153-165

  Wadenberg, Marie Louise G ^a  

^a LINNAEUS UNIVERSITY   (Sweden)

Author keywords

Bifeprunox; Dopamine D2; Partial agonism; Schizophrenia; Serotonin (5 HT)1A; Third generation atypical antipsychotics

Indexed keywords

2 [4 [4 (5 FLUORO 1H INDOL 3 YL) 1,2,3,6 TETRAHYDRO 1 PYRIDINYL]BUTYL]PHTHALIMIDE; 2 DIPROPYLAMINO 8 HYDROXYTETRALIN; 5 [4 [5 (4 FLUOROPHENYL) 3 PYRIDINYLMETHYL] 1 PIPERAZINYL] 1,4 BENZODIOXAN; 8 [4 [3 (5 FLUORO 1H INDOL 3 YL)PROPYL] 1 PIPERAZINYL] 2 METHYL 1,4 BENZOXAZIN 3(4H) ONE; ARIPIPRAZOLE; ATYPICAL ANTIPSYCHOTIC AGENT; BIFEPRUNOX; BUSPIRONE; CLOZAPINE; DOPAMINE 2 RECEPTOR BLOCKING AGENT; HALOPERIDOL; NEUROLEPTIC AGENT; OLANZAPINE; PLACEBO; QUETIAPINE; RISPERIDONE; SEROTONIN 2 ANTAGONIST; TANDOSPIRONE; ZIPRASIDONE;

ADJUVANT THERAPY; AGRANULOCYTOSIS; AKATHISIA; ANOREXIA; ARTICLE; BIPOLAR DISORDER; CARDIOVASCULAR DISEASE; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; COGNITIVE DEFECT; CONSTIPATION; DIZZINESS; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG DOSE COMPARISON; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG FATALITY; DRUG HALF LIFE; DRUG INDUCED HEADACHE; DRUG MECHANISM; DRUG MEGADOSE; DRUG RECEPTOR BINDING; DRUG SAFETY; DRUG STRUCTURE; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSLIPIDEMIA; DYSPEPSIA; DYSTONIA; ELECTROCARDIOGRAM; ENDOCRINE DISEASE; EXTRAPYRAMIDAL SYMPTOM; GASTROINTESTINAL TOXICITY; GLUCOSE BLOOD LEVEL; HEART RHYTHM; HUMAN; HYPERPROLACTINEMIA; HYPOTENSION; INSOMNIA; INSULIN RESISTANCE; LIPID BLOOD LEVEL; LOW DRUG DOSE; METABOLIC DISORDER; METABOLIC SYNDROME X; NAUSEA; NEGATIVE SYNDROME; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PARKINSONISM; PATHOPHYSIOLOGY; PHARMACODYNAMICS; PRIORITY JOURNAL; PROLACTIN BLOOD LEVEL; QT PROLONGATION; RECEPTOR AFFINITY; RISK BENEFIT ANALYSIS; SCHIZOAFFECTIVE PSYCHOSIS; SCHIZOPHRENIA; SEDATION; SIDE EFFECT; SOMNOLENCE; SYNCOPE; TRANQUILIZING ACTIVITY; TRIACYLGLYCEROL BLOOD LEVEL; UNSPECIFIED SIDE EFFECT; VOMITING; WEIGHT CHANGE; WEIGHT GAIN; WEIGHT REDUCTION;

EID: 34249285520     PISSN: 14796708     EISSN: None     Source Type: Journal    
DOI: 10.2217/14796708.2.2.153     Document Type: Article

References (82)

1. Hunziker F, Fisher E, Schmutz J: 1 I-Amino-5H-dibenzo(b,e)-1,4-diazepine-10. Mitteilungen über siebengliedrige Heterocyclen. Helv. Chim. Acta. 50, 1588 (1967).
2. Kane JM, Honigfeld G, Singer J, Meltzer H: Clozapine in treatment-resistant schizophrenics. Psychopharmacol Bull. 24, 62-67 (1988).
3. Kane JM, Marder SR, Schooler NR et al.: Clozapine and haloperidol in moderately refractory schizophrenia: a 6-month randomized and double-blind comparison. Arch. Gen. Psychiatry 58, 965-972 (2001).
4. Meltzer HY, McGurk SR: The effects of dozapine, risperidone, and olanzapine on cognitive function in schizophrenia. Schizophr. Bull. 25, 233-255 (1999).
5. Meltzer HY, Alphs L, Green AI et al.: Clozapine treatment for suicidality in schizophrenia: International Suicide Prevention Trial (InterSePT). Arch. Gen. Pychiatry 60(1), 82-91 (2003).
6. Levinson DF, Simpson G: Serious nonextrapyramidal adverse effects of neuroleptics: sudden death, agranulocytosis, and hepatotoxicity. In: Pychopharmacology: the third generation progress. Meltzer H (Ed.). Raven Press, NY, USA. 1431-1436 (1987).
7. Laruelle M, Abi-Dargham A, van Dyck CH et al.: Single photon emission computerized tomography imaging of amphetamine-induced dopamine release in drug-free schizophrenic subjects. Proc. Natl Acad. Sci. USA 93, 9235-9240 (1996).
8. Weinberger DR, Egan MF, Bertolino, A et al.: Prefrontal neurons and the genetics of schizophrenia. Biol. Pychiatry 50, 825-844 (2001).
9. Abi-Dargham A, Mawlawi O, Lombardo I et al.: Prefrontal dopamine D1 receptors and working memory in schizophrenia. J. Neurosci. 22, 3708-3719 (2002).
10. Castner SA, Williams GV, Goldman-Rakic PS: Reversal of antipsychotic-induced working memory deficits by short-term dopamine D1 receptor stimulation. Science 287, 2020-2022 (2000).
11. Emamian ES, Karayiorgou M, Gogos JA: Decreased phosphorylation of NMDA receptor Type 1 at serine 879 in brains of patients with schizophrenia. J. Neurosci. 24, 1561-1564 (2004).
12. Meltzer HY, Matsubara S, Lee JC: The ratios of serotonin 2 and dopamine 2 affinities differentiate atypical and typical antipsychotic drugs. Pychopharmacol. Bull. 25, 390-2 (1989).
13. Janssen PA, Niemegeers CJ, Awouters F, Schellekens KH, Megens AA, Meert TF: Pharmacology of risperidone (R 64 766), a new antipsychotic with serotonin-S2 and dopamine-D2 antagonistic properties. J. Pharmacol. Exp. Ther. 244 (2), 685-93 (1988).
14. Moore NA, Tye NC, Axton MS, Risius FC: The behavioral pharmacology of olanzapine, a novel 'atypical' antipsychotic agent. J. Pharmacol. Exp. Ther. 262 (2), 545-551 (1992).
15. 2 receptor blocking agent ritanserin in the rat. Eur. Neuropsychopharmacol. 6, 305-310 (1996).
16. Wadenberg, ML, Hicks PB, Richter TJ, Young KA: Enhancement of antipsychotic-like properties of raclopride in rats using the selective 5-HT2A receptor antagonist MDL 100,907. Biol. Pychiatry. 44, 508-515 (1998).
17. Widenberg ML: Antagonism by 8-OH-DPAT, but not ritanserin, of catalepsy produced by raclopride or SCH 23 390 in the rat. J. Neural Transm. 89, 49-59 (1992).
18. Wadenberg ML, Soliman A, VanderSpek SC, Kapur S: Dopamine D2 receptor occupancy is a common mechanism underlying animal models of antipsychotics and their clinical effects. Neuropsychopharmacology 25, 633-641 (2001).
19. Andersson JL, Nomikos GG, Marcus M, Hertel P, Mathé JM, Svensson TH: Ritanserin potentiates the stimulatory effects of raclopride on neuronal activity and dopamine release selectively in the mesolimbic dopaminergic system. Naunyn Schmiedeberg's Arch. Pharmacol. 352, 374-385 (1995).
20. Newcomer JW: Second-generation (atypical) antipsychotics and metabolic effects: a comprehensive literature review. CNS Drugs 19 (Suppl. 1), 1-93 (2005).
21. Wirshing DA, Wirshing WC, Kysar L et al.: Novel antipsychotics: Comparison of weight gain liabilities. J. Clin. Psychiat. 60, 358-363 (1999).
22. Newman-Tancredi A, Assié MB, Leduc N, Ormiere AM, Danty N, Cosi Cr: Novel antipsychotics activate recombinant human and native rat serotonin 5-HTlA receptors: affinity, efficacy and potential implications for treatment of schizophrenia. Int. J. Neuropsychopharmacol. 8, 341-356 (2005).
23. Millan MJ, Gobert A, Newman-Tancredi A et al.: S 16924 ((+)-2-(1-[2-(2,3-dihydrobanzo[1,4] dioxin-5-yloxy)-ethyl]-pyrrolidin-3yl)-1-(4-fluorophenyl)ethanone), a novel, potential antipsychotic with marked serotonin 5-HT1A agonist properties. I. Receptorial and neurochemical profile in comparison with clozapine and haloperidol. J. Pharmacol. Exp. Ther. 286, 1341-1355 (1998).
24. 1A agonist, blocks haloperidol-induced catalepsy by an action of raphe nuclei medianus and dorsalis. Neuropharmacology 27, 515-518 (1988).
25. McMillen BA, Scott SM, Davanzo E: Reversal of neuroleptic-induced catalepsy by novel aryl-piperazine anxiolytic drugs. J. Pharmacol. 40, 885-887 (1988).
26. Wadenberg ML, Ahlenius S: Antipsychotic-like profile of combined treatment with raclopride and 8-OH-DPAT in the rat: Enhancement of antipsychotic-like effects without catalepsy. J. Neural Transm. 83, 43-53 (1991).
27. 3H)8-OH-DPAT and demonstration of increased binding in the frontal cortex in schizophrenia. Neurochem. Internat. 30, 565-574 (1997).
28. Goff DC, Midha KK, Brotman AW, McCormick S, Waites M, Amico ET: An open trial of buspirone added to neuroleptics in schizophrenic patients. J. Clin. Pychopharmacol. 11, 193-197 (1991).
29. Sumiyoshi T, Matsui M, Nohara S et al.: Enhancement of cognitive performance in schizophrenia by addition of tandspirone to neuroleptic treatement. Am. J. Pychiat. 158, 1722-1725 (2001).
30. 1A receptor agonist properties of the antipsychotic nemonapride: comparison with bromerguride and clozapine. Eur. J. Pharmacol. 334, 141-147 (1997).
31. 35S)GTPψS binding study. Eur. J. Pharmacol. 355, 245-256 (1998).
32. Seeger TF, Seymour PA, Schmidt AW et al.: Ziprasidone (CP-88,059): a new antipsychotic with combined dopamine and serotonin receptor antagonist activity. J. Pharmacol. Exp. Ther. 275, 101-113 (1995).
33. Shapiro DA, Renock S, Arrington E et al.: Aripiprazole, a novel atypical antipsychotic drug with a unique and robust pharmacology. Neuropsychopharmacology 28, 1400-1411 (2003).
34. 1A receptor activation. Neuropsychopharmacology 21(5), 622-631 (1999).
35. Malhotra AK, Burdick KE, Razi K, Bates JA, Sanders M, Kane JM: Ziprasidone-induced cognitie enhancement in schizophrenia: Specificity or pseudospecificity? Schizophr. Res. PMI 16820282 87 (1-3), 181-184 (2006) (Epub ahead of print).
36. Meltzer HY, Arato M, O'Connor R: Path analysis of the ZEUS study provides evidence of a direct effect of ziprasidone on primary negative symptoms in chronic, stable schizophrenia. Schizophr. Res. 41(1), 208-209 (2000).
37. Olie JP, Spina E, Murray S, Yang R: Ziprasidone and amisulpiride effectively treat negative symptoms of schizophrenia: results of a 12-week, double-blind study. Int. Clin. Psychopharmacol. 21 (3), 143-151 (2006).
38. Breier A, Berg PH, Thakore JH et al.: Olanzapine versus ziprasidone: results of a 28-week double-blind study in patients with schizophrenia. Am. J. Psychiat. 162 (10), 1879-1887 (2005).
39. Zimbroff DL, Allen MH, Battaglia J et al.: Best clinical practice with ziprasidone IM: update after 2 years of experience. CNS. Spectr. 10 (9), 1-15 (2005).
40. Daniel DG, Zimbroff DL, Potkin SG, Reeves KR, Harrigan EP, Lakshminarayanan M: Ziprasidone 80 mg/day and 160 mg/day in the acute exacerbation of schizophrenia and schizoaffective disorder: a 6-week placebo-controlled trial. Ziprasidone Study Group. Neuropsychopharmacology 20 (5), 491-505 (1999).
41. Swainston Harrison T, Perry CM: Aripiprazole: a review of its use in schizophrenia and schizoaffective disorder. Drugs 64 (15), 1715-1736 (2004).
42. Kane JM, Carson WH, Saba AR et al.: Efficacy and safety of aripiprazole and haloperidol versus placebo in patients with schizophrenia and schizoaffective disorder. J. Clin. Psychiat. 63 (9), 763-771 (2002).
43. Langlois X, Frans A, Megens A et al.: Pharmacology of aripiprazole in rats: A comparison with the classical neuroleptic haloperidol. Int. J. Neuropsychopharmacol. 9 (Suppl. 1), S220 (2006).
44. Bolonna AA, Kerwin RW: Partial agonism and schizophrenia. Br. J. Psychiat. 186, 7-10 (2005).
45. Elsworth JD, Roth RH: Dopamine autoreceptor pharmacology and function. In: I: Dopamine Receptors. Neve RL (Ed.). Humana Press, Totowa, NJ, USA, 232-265 (1997).
46. Clark D, Hjorth S, Carlsson A: Dopamine-receptor agonists: mechanisms underlying autoreceptor selectivity. I. Review of the evidence. J. Neural Transm. 62, 1-52 (1985).
47. Ohmori T, Koyama T, Inoue T, Matzubara S, Yamashita I: B-HT920, a dopamine D2 agonist, in the treatment of negative symptoms of chronic schizophrenia. Biol. Pyschiatry 33, 687-693 (1993).
48. Wetzel H, Hillert A, Grunder G, Benkert O: Roxindole, a dopamine autoreceptor agonist, in the treatment of positive and negative schizophrenic symptoms. Am. J. Psychiat. 151, 1499-1502 (1994).
49. van Vliet BJ, Ronken E, Tulp M, Feenstra R, Kruse CG, Long SK: DU 127090: A highly potent, atypical dopamine receptor ligand - high potency but low efficacy at dopamine D2 receptors in vitro. Eur. Neuropsychopharmacol. 10(Suppl. 3), S293 (2000).
50. 1A receptor affinities. Bioorg. Med. Chem. Letters 11, 2345-2349 (2001).
51. 1A receptor agonism. Schizophr. Bull. 31, 305 (2005).
52. Long SK, Feenstra R, Kruse CG, v an Vliet BJ: DU 127090: A highly potent, atypical dopamine receptor ligand - partial agonist character in neurochemistry assays in vivo. Eur. Neuropsychopharmacol. 10 (Suppl. 3), S295 (2000).
53. Cosi C, Carilla-Durand E, Assié MB et al.: Partial agonist properties of the antipsychotics SSR 181507, aripiprazole and bifeprunox at dopamine D2 receptors: G protein activation and prolactin release. Eur. J. Pharmacol. 535, 135-144 (2006).
54. 2S receptors coupled to extracellular signal-regulated kinase. Eur. J. Pharmacol. 534, 63-70 (2006).
55. Assié MB, Ravailhe V, Faucillon V, Newman-Tancredi A: Contrasting contribution of 5-hydroxytryptamine 1A receptor activation to neurochemical profile of novel antipsychotics: Frontocortical dopamine and hippocampal serotonin release in rat brain. J. Pharmacol Exp. Ther. 315(1), 265-272 (2005).
56. Haddjeri N, Dahan L, Mnie-Filali O, Arnt J, Hertel P: Effects of bifeprunox on the rat ventral tegmental area dopamine and dorsal raphe serotonin neuronal activity. Int. J. Neuropsychopharmacol. 9 (Suppl. 1), S219 (2006).
57. Cussac D, Heusler P, Martel, Newman-Tancredi A: The new antipsychotics, bifeprunox, F15063 and SLV313, behave as partial agonists at dopamine D4 receptors: comparison with typical and atypical antipsychotics. Soc. Neurosci. Abstr. 332.4 (2006).
58. Hertel P, Olsen CK, Didriksen M et al.: Bifeprunox: providing a new option for treating psychosis. Eur. Neuropsychopharmacol. 15 (S3), S486 (2005a).
59. McCreary A: Bifeprunox: A unique, atypical antipsychotic. Eur. Psychiat. 20, S67 (2005).
60. Arnt J, Hesselink MB, Didriksen M, van der Heyden JA, Feenstra RW, Kruse CG: DU127090: A novel partial dopamine agonist with antipsychotic activity, a putative potent full spectrum antipsychotic with low EPS potential. Schizophr. Res. 60(N1,S), 104 (2003).
61. Hertel P, Brennum LT, Helboe L et al.: Bifeprunox: Relationship between antipsychotic potential, EPS liability and dopamine D2 receptor occupancy in rats. Neuropsychopharmacol. 30 (Suppl. 1), 256 (2005b).
62. Hesselink MB, McCreary AC, Glennon JC et al.: Bifeprunox: a novel partial agonist for the D2 receptor with antagonistic capabilities depending on the dopaminergic tone. Eur. Neuropsychopharmacol. 15 (S3), S486 (2005).
63. Hesselink MB, McCreary AC, Ronken E, Feenstra RW, van Kolfschoten A, van Scharrenburg G: DU127090, SLV308 and SLV318: Characterization of a chemically related class of partial dopamine agonists with varying degrees of 5-HT1A agonism. Eur. J. Neurol. 10 (Suppl. 1), S167 (2003).
64. van Kolfschoten A, Hesselink MB, Long SK et al.: DU127090: A novel partial dopamine agonist with antipsychotic activity partial agonist character in functional assays in vivo. Schizophr. Res. 60(N1 S), 117 (2003).
65. Casey DE, van Vliet BJ, Feenstra RW, Kruse CG, Long SK: DU127090: A highly potent, atypical dopamine receptor ligand - Behavioral effects of DU 127090 in Cebus non-human primates. Eur. Neuropsychopharmacol. 10(Suppl. 3), S333 (2000).
66. 1A agonist properties. Neuropsychopharmacol 31(9), 1869-1879 (2006).
67. Kleven MS, Barret-Grévoz C, Bruins-Slot L, Newman-Tancredi A: Novel antipsychotic agents with 5-HT1A agonist properties: Role of 5-HT1A receptor activation in attenuation of catalepsy induction in rats. Neuropharmacology 49, 135-143 (2005).
68. 1A receptor activation and dopamine D2 receptor blockade. Neuropsychopharmacol. 31(9), 1900-1909 (2006).
69. 1A agonist properties on PCP-induced social interaction deficits in the rat. Neuropharmacology 49, 996-1006 (2005).
70. 1A properties. Soc. Neurosci. Abstr. 666.19 (2006).
71. Hertel P, Husum H, Marquis K, Herremans AHJ, Hesselink MB: Bifeprunox: a novel atypical antipsychotic with in vivo 5-HT1A receptor agonistic activity. Schizophr. Res. 81(Suppl. 1), 83 (2006).
72. Putman M, Katuin G, Hjort Christensen L, Pratt G: Challenges in determining the protein binding of two in all aspects very different analytes in one plasma sample: bifeprunox and valproate. Presented at: FABIAN Symposium. Organon, OSS, The Netherlands (2005).
73. 11C-raclopride by means of positron emission tomography. Eur. Neuropsychopharmacol. 10(Suppl. 3), S293 (2000).
74. 11 C-raclopride by means of positron emission tomography. Schizophr. Res. 60(N1,S), 239-240 (2003).
75. de Vries MH, Grahnén A, Nyman L et al.: Bifeprunox: Dopamine D2 receptor occupancy. Biol. Psychiatry 60, (2006) (In Press).
76. Rapaport M, Barbato LM, Heisterberg J, Yeung PP, Shapira NA: Efficacy and safety of bifeprunox versus placebo in the treatment of patients with acute exacerbations of schizophrenia. Presented at: ACNP Meeting. Hollywood, FL, USA, December 3-7 (2006).
77. Casey D, Barbato LM, Heisterberg J, Yeung PP, Shapira NA: Efficacy and safety of bifeprunox in the treatment of patients with acute exacerbations of schizophrenia: Results of a dose-finding study. Presented at: ACNP Meeting. Hollywood, FL, USA, December 3-7 (2006).
78. Barbato LM, Potkin SG, Heisterberg J, Yeung PP, Shapira NA: A randomized, double-blind, placebo-controlled study of bifeprunox, a partial dopamine D2 receptor agonist, in patients with acute exacerbations of schizophrenia. Presented at: ACNP Meeting. Hollywood, FL, USA, December 3-7 (2006).
79. Bourin M, Debelle M, Heisterberg J et al.: Long-term efficacy and safety of bifeprunox in patients with schizophrenia: A 6-month, placebo-controlled study. Presented at: ACNP Meeting. Hollywood, FL, USA, December 3-7 (2006).
80. Shapiro NA, Newcomer JW, Barbato LM, Heisterberg J, Yeung PP: The metabolic profile of bifeprunox in the treatment of patients with schizophrenia. Presented at: ACNP Meeting. Hollywood, FL, USA, December 3-7 (2006).
81. Wolf W: DU-127090 Solvay/Lundbeck. Curr. Opin. Investig. Drugs 4 (1), 72-76 (2003).
82. Johnston LC, McCreary AC, Rose S, Smith L, Jackson M, Jenner P: Association between intrinsic activity and the antiparkinsonian effect of a novel dopamine D2 agonist series in the 1-methyl-4-phenyl-1,23,6-tetrahydropyridine treated primate model of Parkinson's disease. Eur. J. Neurol. 10 (Suppl. 1), S169 (2003).